Volv Global CEO Christopher Rudolf speaks at the DREAMS Neuromuscular Disease AI Webinar
Volv Global CEO Christopher Rudolf will speak at the DREAMS Neuromuscular Disease AI Webinar
Volv Global generates insights that create new understanding of disease progression and the patient journey, closing the gap between disease onset and effective treatment.
We help transform lives by giving pharmaceutical innovators powerful insights into difficult-to-diagnose diseases so they can develop effective tools and treatments.
For people living with these diseases, the aim is a shorter road to diagnosis and better treatments, through the pharmaceutical partners who develop them.
Volv Global works directly with the pharmaceutical companies developing the next generation of therapies. Volv Global does not give medical advice and cannot assess individual patients. Please speak to your doctor, or one of the organisations below..
Recognising that patients living with difficult-to-diagnose diseases may also arrive on our pages, we attempt, below, to offer a few lists of resources for possible approach. This list is necessarily incomplete, and we will continue to update it as we learn more.
Please note: Volv Global has no official affiliation with any of the organisations mentioned on this page.
Volv Global started in rare and difficult-to-diagnose diseases
Rare diseases manifest in less than one person among thousands. Doctors have less experience with them, and developers of therapies and payers have less patients to draw understanding from … leaving patients in a healthcare limbo.
Depending on definitions of “rare,” over 300 million people – or 3.5-5.9% of the world population – suffer from 6,000-10,000 rare diseases.
Please note: Volv Global has no official affiliation with these organisations.
Upon diagnosis, patients need a deep and thorough understanding of the disease and the likelihood of how the disease will progress.
Patients also require support to understand treatment options, as well as availability in their geographical location. In certain cases, awareness of available clinical research trials may be useful.
Rare Rebels: A Storytelling Movement to Support the Rare Disease Community
Please note: Volv Global has no official affiliation with these organisations.
Go deeper
Volv Global CEO Christopher Rudolf will speak at the DREAMS Neuromuscular Disease AI Webinar
Volv Global at the 25th Annual NEALS Meeting, presenting new research on early identification of ALS using advanced M...
Presenting new research on whether a machine learning model can flag which patients with CAP are most likely to progr...
Results for the model flagging early ARDS risk in pneumonia will be presented at ERS Congress 2026.
Volv Global at ERS Congress 2026, presenting new research in collaboration with CSL Behring: Can We Catch ARDS Before...
Volv Global applied machine learning to 24M UK primary care records, surfacing ~1,200 undiagnosed GEP-NET patients, 5...
GEP-NETs are among the most diagnostically elusive tumours in oncology. This case study shows how machine learning ap...
Machine learning applied to 3,549 confirmed Pompe disease patients – the largest machine learning study of the diseas...
New research demonstrates that machine learning can map clinician-defined endpoints to real-world claims data in Pomp...
Explore Volv Global’s ISPOR 2026 research with Sanofi on Pompe disease, based on use of machine learning-driven endpo...
In Inflammatory Bowel Disease (IBD), steroids are considered a routine treatment, but repeated steroid exposure is a ...
AI-driven insights & RWD in Rare Disease: Accelerate AATD Diagnosis and identify undiagnosed AATD patients earlie...